Summary of 2009 financial information Shareholder information Available online...
Sales of 28.4 billion, up 3%, with successful delivery of More information on www.
com diversification strategy This document contains a summary of certain information in our Annual Report for the year ended 31 December 2009 New pharmaceutical pr oducts launched since 2007, excluding H1N1 and does not include all the information needed to give pandemic vaccine, contributed 1.3 billion a full understanding of the results, state of affairs, risks and 1 billion annual savings deliver ed by major restructuring programme uncertainties of the company and the Group as is provided by the full financial statements, Directors Report, Remuneration Net cash inflow fr om operating activities 7.8 billion, Report and Auditors Report contained in the Annual Report.
up 9% in sterling terms The Annual Report and the Notice of Annual General Meeting EPS befor e major restructuring of 121.2p, up 2%.
Total EPS of are available at www.
com annualreport 109.1p, up 8% Dividend of 61p, up 7% The Annual Report and Notice of Annual General Meeting are available at Unless otherwise stated, all percentage increases are at constant exchange rates CER www.
com annualreport to illustrate underlying performance.
Annual General Meeting The GSK Annual General Meeting will be held at 2:30pm on Thursday 6 May 2010 at: Dividends The Queen Elizabeth II Conference Centre Dividend Payment date 2009 pence 2008 pence Broad Sanctuary First interim 9 July 2009 14 13 Westminster Second interim 8 October 2009 14 13 London SW1P 3EE 2009 was a year of significant change for GSK.
Third interim 7 January 2010 15 14 Keeping up to date Fourth interim 8 April 2010 18 17 Should you choose to receive future notifications from us Total 61 57 by email, please register accordingly on www.
To review our progress visit You can request printed copies of our financial report from Dividend calendar www.
com annualreport Equiniti and The Bank of New York Mellon.
Quarter Ex-dividend date Record date Payment date Shareholder and investor contacts Q4 2009 10 Feb 2010 12 Feb 2010 8 Apr 2010 Security type Contact address Telephone Q1 2010 5 May 2010 7 May 2010 8 Jul 2010 Q2 2010 28 July 2010 30 Jul 2010 7 Oct 2010 Ordinary shares, Aspect House 0871 384 2991 Q3 2010 27 Oct 2010 29 Oct 2010 6 Jan 2011 administered by Spencer Road inside the UK Equiniti Limited Lancing BN99 6DA 44 0 121 415 7067 outside the UK Financial advice ADRs, administered BNY Mellon 1 877 353 1154 The provision of the details on this page is not intended to be by the Bank of Shareowner Services US toll free an invitation or inducement to engage in an investment activity.
New York Mellon PO Box 358516 1 201 680 6825 Advice on share dealing should be obtained from a stockbroker Pittsburgh outside the USA or independent financial adviser.
PA 15252-8516 Cautionary statement Under the safe harbor provision of the US Private Securities Litigation Reform Act of 1995, the company cautions shareholders that any forward looking statements or projections made by the company, including those made GSK is changing in this document, are subject to risks and uncertainties that may cause actual results to differ materially from those Results and strategic priorities 2009 projected.
Factors that may affect the Groups operations are described under Risk factors in the Business Review in the companys Annual Report 2009.
